True Mark W
US Air Force Medical Corps, Endocrinology Service, Lackland Air Force Base, Texas 78236, USA.
J Diabetes Sci Technol. 2009 Jul 1;3(4):743-7. doi: 10.1177/193229680900300421.
Personalized medicine represents a new model in how the medical community approaches disease management. Rather than managing those with a particular diagnosis according to an established guideline, the personalized medicine model seeks to identify unique characteristics within each patient that can serve as a basis for disease characterization and specialized treatment. This article reviews several circulating biomarkers of glycemia that are used in the medical management of diabetes, to include hemoglobin A1c, fructosamine, and 1,5-anhydroglucitol. Within the discussion, specific attention is paid to areas in which biomarker results do not correlate with anticipated results based on actual mean glycemia. Variability between actual and anticipated results of the various biomarker tests represents opportunities to identify previously undefined subcategories of diabetes and groups of patients that fit into these subcategories. Finally, research areas are proposed for these subcategories that would further promote the field of personalized medicine in diabetes.
个性化医疗代表了医学界处理疾病管理的一种新模式。与按照既定指南管理特定诊断的患者不同，个性化医疗模式旨在识别每个患者的独特特征，这些特征可作为疾病特征描述和专门治疗的基础。本文综述了几种用于糖尿病医疗管理的血糖循环生物标志物，包括糖化血红蛋白、果糖胺和1,5-脱水葡萄糖醇。在讨论中，特别关注生物标志物结果与基于实际平均血糖水平的预期结果不相关的领域。各种生物标志物检测的实际结果与预期结果之间的差异代表了识别先前未定义的糖尿病亚类以及适合这些亚类的患者群体的机会。最后，针对这些亚类提出了研究领域，这将进一步推动糖尿病个性化医疗领域的发展。
